S. Gill

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

J. Bendell, T. Alcindor, P. Tang, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I–II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)

G. Pond, S. Gill, J. Knox, 2008, Investigational New Drugs.

Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer

A. Oza, T. Ketela, S. Lheureux, 2022, Cancer research communications.

A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.

T. Stockley, E. Chen, D. Graham, 2021, Lung cancer.

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

M. Tsao, D. Hedley, M. Moore, 2014, European journal of cancer.

Phase II trial of erlotinib in advanced pancreatic cancer (PC).

D. Hedley, M. Moore, H. Au, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer

T. Price, A. Dean, V. Broadbridge, 2020 .